Real-World Treatment Patterns of US Patients With Platinum-Resistant Ovarian Cancer
Author(s)
Neeraj N. Iyer, PhD1, Rachel Bhak, MS1, Vijay Joish, PhD1, Tongsheng Wang, MS1, Keren Zhang, PhD1, Audrey Hopkins, PhD1, Ibrahima Soumaoro, MD1, Edward Kavalerchik, MD1, Ritu Salani, MD2.
1Genmab US Inc, Plainsboro, NJ, USA, 2University of California Los Angeles, Los Angeles, CA, USA.
1Genmab US Inc, Plainsboro, NJ, USA, 2University of California Los Angeles, Los Angeles, CA, USA.
OBJECTIVES: Initial treatment for ovarian cancer includes platinum-based therapy, but most patients with advanced disease progress to platinum-resistant ovarian cancer (PROC). This study aimed to understand treatment patterns for PROC in a real-world setting.
METHODS: This was a retrospective study using US Flatiron Health electronic health record data (2011-2024). Patients with advanced OC (stage III/IV) and PROC (progression <6 months after last platinum dose) were included. Index treatment for PROC was defined as the regimen following PROC development. Treatment patterns include regimens received for index treatment for PROC and subsequent line of therapy (LOT), time to next treatment (TTNT), and time to treatment discontinuation (TTD), via Kaplan-Meier median and 95% confidence interval (CI).
RESULTS: Of 774 patients included, median age at diagnosis was 67 years, and 70.4% were White, 7.1% Black, 22.5% other/unknown. PROC treatment initiation was between 2011-2015 for 12.0%, 2016-2020 for 47.7%, and 2021-2024 for 40.3%. The median number of prior LOTs before developing PROC was 1. For index PROC treatment, 37.0% received single-agent non-platinum chemotherapy, 32.2% received bevacizumab-containing regimen, 14.7% received platinum-based therapy, 3.9% received mirvetuximab soravtansine (MIRV),12.3% received other regimens. For those receiving another subsequent LOT (57.8%), 43.3% received single-agent non-platinum chemotherapy, 21.2% received bevacizumab-containing regimen, 14.9% received platinum-based therapy, 4.3% received MIRV, 16.3% received other regimens. Median (95% CI) TTNT and TTD for index PROC treatment was 5.4 (4.1, 6.3) and 3.0 (2.5, 4.0) months for those treated with platinum, 4.1 (3.8, 4.4) and 2.7 (2.5, 2.9) months for those treated without platinum, and 4.5 (2.7, 7.3) and 3.9 (2.5, 6.6) months for those treated with MIRV, respectively.
CONCLUSIONS: In advanced ovarian cancer, treatment options are limited following platinum resistance, with some patients continuing to receive platinum despite limited benefit. TTNT and TTD are short for patients with PROC, highlighting the unmet need in this population.
METHODS: This was a retrospective study using US Flatiron Health electronic health record data (2011-2024). Patients with advanced OC (stage III/IV) and PROC (progression <6 months after last platinum dose) were included. Index treatment for PROC was defined as the regimen following PROC development. Treatment patterns include regimens received for index treatment for PROC and subsequent line of therapy (LOT), time to next treatment (TTNT), and time to treatment discontinuation (TTD), via Kaplan-Meier median and 95% confidence interval (CI).
RESULTS: Of 774 patients included, median age at diagnosis was 67 years, and 70.4% were White, 7.1% Black, 22.5% other/unknown. PROC treatment initiation was between 2011-2015 for 12.0%, 2016-2020 for 47.7%, and 2021-2024 for 40.3%. The median number of prior LOTs before developing PROC was 1. For index PROC treatment, 37.0% received single-agent non-platinum chemotherapy, 32.2% received bevacizumab-containing regimen, 14.7% received platinum-based therapy, 3.9% received mirvetuximab soravtansine (MIRV),12.3% received other regimens. For those receiving another subsequent LOT (57.8%), 43.3% received single-agent non-platinum chemotherapy, 21.2% received bevacizumab-containing regimen, 14.9% received platinum-based therapy, 4.3% received MIRV, 16.3% received other regimens. Median (95% CI) TTNT and TTD for index PROC treatment was 5.4 (4.1, 6.3) and 3.0 (2.5, 4.0) months for those treated with platinum, 4.1 (3.8, 4.4) and 2.7 (2.5, 2.9) months for those treated without platinum, and 4.5 (2.7, 7.3) and 3.9 (2.5, 6.6) months for those treated with MIRV, respectively.
CONCLUSIONS: In advanced ovarian cancer, treatment options are limited following platinum resistance, with some patients continuing to receive platinum despite limited benefit. TTNT and TTD are short for patients with PROC, highlighting the unmet need in this population.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD98
Topic
Clinical Outcomes, Health Service Delivery & Process of Care
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology